Improving outcome in newly diagnosed malignant glioma

Abstract

In 2013, two discoveries-that alkylating agent chemotherapy prolongs survival when added to radiotherapy for patients with anaplastic oligodendroglial tumours with 1p19q codeletion, and that bevacizumab prolongs progression-free survival in patients with newly diagnosed glioblastoma-have dominated debate in neuro-oncology. These findings could help to define new standards of care in malignant glioma. promoter methylation, and isocitrate dehydrogenase (IDH) 1 or 2 mutation, and the introduction of temozolomide (TMZ) chemoradiotherapy for newly diagnosed

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

“…For optimal management of patients with anaplastic gliomas, there is a clinical need for reliable information on IDH, 1p/19q, MGMT, and ATRX status. 22,23 Of note, ATRX is not prognostic for the full dataset (Supplementary material, Fig. 4A), but ATRX loss helps to identify the better-prognosis anaplastic astrocytoma (P ¼ .02) (Supplementary material, Fig.…”

LRG1 modulates invasion and migration of glioma cell lines through TGF-β signaling pathway

“…To date, the molecular mechanisms underlying the tumorigenesis and progression of glioma are poorly understood, and glioma remains the focus of concern in the field of neurosurgery. With recent technological advancement, a number of genes related to the development of glioma have been identified (Kondo et al, 2014;Weller and Wick, 2014), providing new directions for the research into the diagnosis and treatment of glioma.…”

MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape

“…Glioblastomas are intrinsic tumors of the brain with a poor prognosis despite comprehensive therapeutic strategies [ 1 ]. They are characterized by diffuse infiltration of the healthy brain, well-adapted to a hypoxic environment and poorly immunogenic, precluding potent anti-tumor immune responses.…”